Tirzepatide
FDA-approved dual GIP + GLP-1 receptor co-agonist · once-weekly (SC)
Tirzepatide is an FDA-approved dual agonist — a single peptide that switches on two gut-hormone receptors at once, the GIP receptor and the GLP-1 receptor — and it is the defining difference from GLP-1-only drugs like semaglutide. It is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea. It is the most effective weight-loss medicine with published trial data to date: in the SURMOUNT-1 obesity trial the 15 mg dose produced about 20.9% mean weight loss over 72 weeks, and in a head-to-head trial (SURPASS-2) it beat semaglutide on both blood-sugar and weight outcomes. The honest framing: the dual mechanism is a real, clinically demonstrated advantage, but exactly how much the GIP arm contributes is inferred rather than directly measured; the same gut side effects that affect the whole class still dominate and drive discontinuations; and weight is regained after stopping.
The short version
Tirzepatide is a man-made peptide that copies and combines two of the body's after-meal gut hormones at once. One is GLP-1 (the same target as Ozempic and Wegovy); the other is GIP. Hitting both receptors with a single molecule is what makes tirzepatide a "dual agonist," and it is the headline difference from the GLP-1-only drugs.
It is an approved medicine sold under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management, and more recently for obstructive sleep apnea in people with obesity). It is given as a once-weekly injection under the skin.
In trials it produced the largest weight loss of any approved drug so far — around 21% at the top dose over about 72 weeks — and it outperformed semaglutide when the two were compared directly. The dual-hormone idea is a genuine advantage, but it is also a marketing story: the superiority is proven, while the exact share the GIP arm contributes is an educated inference, not something measured separately in people.
Molecular identity
Specs
- Molecular weight
- 4813.53 Da
- Molecular formula
- C225H348N48O68
- Monoisotopic mass
- 4810.52 Da
- Amino acids
- 39-residue GIP-based backbone
- Structure / class
- Dual GIP/GLP-1 receptor co-agonist; Aib at positions 2 and 13, C-terminal amide, Lys20 with C20 fatty-diacid linkerDailyMed (Mounjaro)
- CAS / UNII
- 2023788-19-2 · OYN3CCI6QEPubChem CID 156588324; FDA UNII
- Molecular target
- GIP receptor + GLP-1 receptor (dual agonist)DailyMed (Mounjaro)
- Brand / approval
- FDA-approved — Mounjaro (T2D), Zepbound (obesity & OSA)FDA label
- Regulatory status
- FDA-approved drug; WADA 2026 Monitoring Program (monitored, not prohibited)FDA / WADA 2026
Plain English
Mechanism
Tirzepatide is the first dual incretin agonist — "incretins" are gut hormones released after eating that prompt the pancreas to release insulin, and "agonist" means a molecule that switches a receptor on. It activates two of them at once.
The GLP-1 receptor arm reproduces the familiar GLP-1 effects: glucose-dependent insulin secretion (more insulin, but only when blood sugar is high), glucagon suppression, slowed gastric emptying (food leaves the stomach more slowly, so you feel full longer), and action on appetite centers in the brain. The GIP receptor arm is the added piece: GIP (glucose-dependent insulinotropic polypeptide) also enhances insulin secretion and is thought to contribute to better fat/lipid handling and appetite regulation.
Why the dual approach may outperform GLP-1 alone: in the SURPASS-2 head-to-head trial, tirzepatide produced larger reductions in both HbA1c (a long-term blood-sugar marker) and body weight than semaglutide. The leading explanation is additive or synergistic signaling from engaging both receptors. The important honesty point: that clinical superiority is demonstrated, but the specific causal contribution of the GIP arm is an inference — it has not been isolated and measured in humans. The dual mechanism is best described as an evidence-supported advantage in head-to-head outcomes, not as "proven because GIP does X."
Sources:PMID 34170647DailyMed (Mounjaro)
Why people reach for it
Potential benefits
Tirzepatide is the current high-water mark for weight-loss medicines — here's what draws people to it, with the honest caveats kept in frame.
- The largest weight loss of any approved drug — Its headline appeal, and it's backed by real human trials: in SURMOUNT-1 the 15 mg dose produced about 20.9% mean body-weight loss over 72 weeks — the biggest figure of any approved weight-loss medicine with published data.
- It outperformed Semaglutide head-to-head — In the SURPASS-2 trial it beat Semaglutide on both blood-sugar and weight outcomes — the dual GIP + GLP-1 mechanism is a real, clinically demonstrated edge, not just a marketing line.
- Appetite and food noise turned down hard — By engaging two gut-hormone receptors that slow the stomach and act on appetite centers, it makes a calorie deficit far easier to hold — the main driver behind the weight numbers.
- Strong blood-sugar control — As approved Mounjaro for type 2 diabetes, its dual incretin action drives glucose-dependent insulin and lowers HbA1c more than GLP-1 alone in the trials.
- A treatment for sleep apnea too — Zepbound is the first drug approved specifically for obstructive sleep apnea in people with obesity (SURMOUNT-OSA), broadening what people pursue it for beyond the scale.
- A once-weekly rhythm that's easy to keep — Its long half-life means one injection a week on a fixed day, with no meal timing to manage — a low adherence burden for an agent this powerful.
Sources:PMID 35658024PMID 34170647PMID 38912654DailyMed (Mounjaro)
What people reach for Tirzepatide for, based on what the trials report and how it's used — real approved outcomes, but paired with their honest costs (GI side effects that drive discontinuations, some lean-mass loss, regain after stopping), not a cure or a guarantee.
Implied timing
Best time to dose
Implied best time
Anytime (consistent, weekly)
Most people take Tirzepatide on one fixed day each week — the day you hold it matters, the clock does not.
- Its half-life is about 5 days, so blood levels stay broadly steady across the week — there is no daily peak to align with food or a clock. Holding the same weekday (the ±1-day window is forgiving) is what keeps levels even; the hour is your choice.
- Effects build over weeks: appetite suppression deepens through the slow titration and weight loss accrues over months, so the timing of any single dose does not change the outcome — week-to-week consistency does.
- It can be injected with or without food, any time of day; meal timing has no effect on the subcutaneous dose.
- The main day-to-day variable is nausea, worst during titration — so some people pick a low-key day for the dose so any queasiness lands when it's least disruptive.
No study establishes an ideal time of day for Tirzepatide — this is reasoned from its ~5-day half-life and how it's used. The usual peptide-dosing default is the midday-to-evening window, but for a once-weekly agent the real lever is the same weekday each week, not the hour.
Sources:DailyMed (Mounjaro)
How to run it
Dosing & protocol
Tirzepatide is an FDA-approved once-weekly subcutaneous injection — the titration ladder below is the real FDA-label schedule (Mounjaro / Zepbound), not a community convention. Titration IS the protocol: the GI side effects are dose-related, and a slow 4-week escalation per step is what keeps them manageable.
FDA-approved drug (Mounjaro / Zepbound) — schedule below is the label-approved titration. WADA 2026: monitored program, NOT prohibited. This page presents the approved regimen for educational context; tirzepatide requires a prescription in all markets.
Titration schedule
Start low and hold each step for 4 weeks — GI tolerance is built, not rushed.
- Starter (weeks 1–4):
- 2.5 mg SC once weekly — tolerability dose only, not therapeutic maintenance. Hold the full 4 weeks regardless of tolerance.
- Step 2 (weeks 5–8):
- 5 mg SC once weekly — first maintenance-range dose. Hold minimum 4 weeks.
- Steps 3–6 (every ≥4 wk):
- Increase by 2.5 mg increments: 7.5 → 10 → 12.5 → 15 mg weekly, advancing only as tolerated. Maximum approved adult dose: 15 mg weekly.
- Approved maintenance doses:
- Zepbound (obesity/OSA): 5, 10, or 15 mg weekly. Mounjaro (T2D pediatric, ≥10 yr): max 10 mg weekly.
- Held step:
- If a step triggers significant nausea, vomiting, or constipation, hold at the current dose for an additional 4 weeks before attempting the next increment — the label supports this.
Subcutaneous administration
Once-weekly SC injection — the long interval is structural: the C20 fatty-diacid linker binds tirzepatide to albumin for a ~5-day half-life.
- Injection site:
- Abdomen (at least 2 inches from the navel), outer thigh, or upper arm. Rotate sites weekly so no single area takes every injection — prevents lipohypertrophy and irritation.
- Day of week:
- Any consistent day of the week; the ~7-day interval is forgiving (±1 day is fine). Picking a specific day (e.g. Sunday) reduces missed-dose risk.
- Food window:
- No food window required — tirzepatide can be injected with or without food, any time of day. Consistency with the day matters; the meal-timing does not.
- Missed dose:
- If a dose is missed by ≤4 days, inject as soon as remembered, then resume the normal schedule. If >4 days have elapsed, skip that dose and resume on the next regular day — do not double up.
Duration & stopping
Tirzepatide is chronic therapy, not a cycled peptide. Benefit depends on continued use.
- Duration:
- Open-ended. There is no washout phase or on/off cycle — approved maintenance runs as long as the indication (T2D management or weight management) persists.
- Weight regain on stopping:
- Weight regain after stopping is well documented in trial extensions. The SURMOUNT-4 withdrawal arm saw substantial regain within 52 weeks of stopping — the drug holds the set point while on; the set point reverts when off. This is a Class property, not a tirzepatide quirk.
- GI adaptation timeline:
- Most GI side effects peak during titration and improve at stable maintenance dose. If GI effects persist past the first maintenance step, staying at that step for an additional cycle before increasing is the standard approach.
Reconstitution at a glance
Calculator defaults for research-grade tirzepatide vials (not the approved pen — the pen is pre-filled):
- Default mix:
- 10 mg vial + 2 mL bacteriostatic water = 5 mg per mL. On a 100-unit (1 mL) insulin syringe: 2.5 mg = 50 IU · 5 mg = 100 IU.
- Weekly-dose units:
- 2.5 mg = 50 IU · 5 mg = 100 IU · 7.5 mg = 150 IU · 10 mg = 200 IU · 12.5 mg = 250 IU · 15 mg = 300 IU (at 5 mg/mL).
Sources:DailyMed (Mounjaro)PMID 35658024
Substrate the signal needs
Nutritional cofactor precision
Tirzepatide cuts appetite hard and slows gastric emptying — producing up to ~21% weight loss. That scale of deficit creates three simultaneous nutritional demands: mitigate GI side effects (the dominant cost), preserve lean mass (the biggest long-term risk), and cover micronutrient gaps that a smaller plate quietly opens.
Reasoned from incretin physiology and mainstream weight-loss nutrition — not a tirzepatide supplement trial. Supplement doses are standard evidence-based ranges; every number here is for the co-intervention, not the drug.
Mitigate nausea (peak during titration)
GI side effects are dose-related and worst during escalation — these reduce them without blunting the drug.
- Ginger extract:
- 1–2 g standardized ginger (5% gingerols) taken 30 min before the weekly injection and for 1–2 days after during titration steps. Ginger's 5-HT3 antagonism addresses the same nausea pathway tirzepatide triggers via slowed gastric emptying.
- Vitamin B6 (pyridoxine):
- 25–50 mg at bedtime on injection day — the same B6 rationale behind pregnancy nausea protocols. Modest but additive with ginger.
- Meal composition:
- Low-fat, small, protein-and-vegetable meals during titration. High-fat meals dramatically worsen nausea when gastric emptying is already slowed — this is behavioral mitigation, not a supplement.
Mitigate constipation (chronic low fiber + dehydration)
Constipation is the second most common persistent side effect — not just a GI nuisance, it compounds discomfort and drives discontinuations.
- Magnesium bisglycinate:
- 300–400 mg at bedtime daily. Osmotic stool-softening effect plus the magnesium repletion that eating less (and any GI losses) creates — two jobs, one supplement.
- Soluble fiber:
- 10–15 g psyllium husk (or equivalent) daily in divided doses, ramped up over 2 weeks to tolerance. Adds bulk and feeds the microbiome that tirzepatide's longer gut transit is now engaging more deeply.
- Hydration:
- At least 2–2.5 L water daily. Eating significantly less means drinking significantly less by default — dehydration is underappreciated as a constipation driver on this class.
Preserve lean mass (the most important cofactor group)
~20% weight loss at this speed will include muscle unless protein and resistance training are non-negotiable. Muscle loss is the primary long-term cost.
- Protein target:
- 1.6–2.0 g per kg bodyweight per day — aim for the upper end (2.0 g/kg) in a deep caloric deficit. With appetite this suppressed, hitting protein requires deliberate sequencing: protein first at every meal before anything else.
- Resistance training:
- 2–3 sessions per week of progressive resistance training is the mechanistic anchor for lean-mass preservation — no supplement replaces the anabolic signal of loading muscle. Prioritize this before adding any supplement below.
- Creatine monohydrate:
- 3–5 g daily. Supports muscle protein synthesis and power output under a caloric deficit; safe, cheap, and the most evidence-backed lean-mass supplement available. Take with the protein meal or post-workout.
Cover electrolyte & micronutrient gaps
Eating 40–60% fewer calories quietly opens deficits that a smaller plate cannot close — especially when GI losses add to the drain.
- Electrolytes (Na / K / Mg):
- Electrolyte supplement providing ~500 mg sodium, ~1,000 mg potassium, and ~200 mg magnesium daily (adjust to diet). Fatigue, muscle cramps, and headaches during initial weight loss are often electrolyte depletion, not drug side effects.
- Multivitamin + key targets:
- A comprehensive daily multivitamin as insurance. Specifically verify B12 (absorption can shift with GI motility changes), iron (women especially), and calcium (1,000–1,200 mg/day from food + supplement combined).
- Vitamin D:
- Dose to a serum 25(OH)D in the sufficient range (typically 40–60 ng/mL). Obesity is associated with functional vitamin D deficiency at baseline — fat-mass loss improves distribution but does not automatically correct a pre-existing deficit.
Combinations + timing
Stacking notes + timing windows
Tirzepatide already activates both the GLP-1 and GIP receptors — it is the dual incretin. Adding a single-GLP-1 agonist (semaglutide, liraglutide) hits the same levers it already covers. The genuinely complementary axes are the ones tirzepatide does not touch: amylin signaling (appetite suppression via a different receptor) and lean-mass protection (the main metabolic cost of a ~20% weight loss).
Tirzepatide + cagrilintide is mechanism-reasoned, not trial-tested — CagriSema studies use semaglutide as the incretin partner, not tirzepatide. All stacks here are reasoned from complementary biology; none are approved co-administrations. Doses are community convention.
Tirzepatide + Cagrilintide (amylin axis — the complementary satiety arm)
The redundancy-honest pairing: tirzepatide covers GLP-1 + GIP; Cagrilintide adds amylin-receptor satiety — a genuinely different mechanism.
- Why it works:
- Cagrilintide is a long-acting amylin analog that slows gastric emptying and suppresses appetite via the amylin receptor — distinct from the incretin pathway tirzepatide already saturates. CagriSema (cagrilintide + semaglutide) trial data showed additive weight loss over either component alone, which is the mechanistic rationale here. The important honesty: that specific trial used semaglutide as the incretin partner; tirzepatide + cagrilintide is mechanism-extrapolated, not head-to-head tested.
- The protocol:
- Tirzepatide at the established maintenance dose (5–15 mg SC weekly) + Cagrilintide on its own titration (typically 0.3 mg SC weekly, escalating to 2.4 mg over several weeks). Both are weekly SC injections; they can be given on the same day at different sites or on different days.
- Outcome:
- The combination users and investigators reason toward for maximum satiety coverage — two complementary hormonal brakes (incretin + amylin) rather than two incretins. The redundancy problem you avoid: adding semaglutide to tirzepatide would push the same GLP-1 lever twice. This does not.
Tirzepatide + lean-mass protection stack (ipamorelin / CJC-1295 + creatine)
Addresses tirzepatide's primary metabolic trade-off: rapid, large weight loss takes muscle unless the anabolic signal is protected.
- Why it works:
- At ~20% weight loss, the caloric deficit and appetite suppression together suppress GH pulsatility and create a catabolic environment. A GH secretagogue — Ipamorelin (selective GH release, no cortisol/prolactin spike) or CJC-1295 (GHRH analog, longer-acting) — restores the GH signal that protects lean mass during the deficit. Creatine supports muscle energy turnover and protein synthesis under the same conditions. These are not redundant with tirzepatide — they operate on a completely different axis (GH/IGF-1 and creatine-phosphate) while tirzepatide is running the metabolic side.
- The protocol:
- Ipamorelin 200–300 mcg SC 2–3x daily (or CJC-1295 without DAC 100–200 mcg SC 2–3x daily) + creatine monohydrate 5 g daily (covered in cofactors above, included here for completeness). GH secretagogues are run on a peptide cycle (8–12 wk on / 4 wk off); tirzepatide continues its own weekly schedule unchanged.
- Outcome:
- The combination users reach for when a large, rapid weight-loss run creates visible muscle loss alongside the fat loss — the goal is preserving the lean-tissue fraction of the total loss, not blocking weight loss overall.
Reconstitution math
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
50
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.5 mL
- Doses per vial
- 4
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 4 days
- Every other day
- 8 days
- 5×/week
- 5 days
- Large draw (50 units). Double-check the vial size and dose — a mcg/mg mix-up produces values like this.
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
From the studies
Side effects from research
Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors: in rats it caused dose- and duration-dependent thyroid C-cell tumors at clinically relevant exposures, and it is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in humans — a precise statement that neither dismisses nor overstates the rodent finding. It is contraindicated in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The most common adverse effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal pain — which are dose-related, worst during titration, and the main driver of discontinuations. Other labeled warnings include acute pancreatitis, gallbladder disease (gallstones, cholecystitis), acute kidney injury from dehydration during heavy GI symptoms, hypoglycemia when combined with insulin or sulfonylureas, and transient worsening of diabetic retinopathy as blood sugar improves rapidly.
The honesty caveat shared with the whole class: weight regain after stopping is well documented, so the benefit requires continued use rather than being a one-time result.
Sources:DailyMed (Mounjaro)PMID 35658024
As reported in literature
Research dosing ranges
These are the doses tested in the major published trials, shown separately so the trial evidence is never mistaken for a recommended regimen. Tirzepatide's evidence base is large, randomized, and human — including a direct head-to-head against semaglutide and the first drug trial to win an approval specifically for obstructive sleep apnea. All doses were given as the approved once-weekly subcutaneous injection, reached by gradual escalation, under medical supervision.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| 5 / 10 / 15 mg | SC weekly (40 wk) | Human (SURPASS-2, T2D, head-to-head vs semaglutide 1 mg, n=1,879) | HbA1c −2.01 / −2.24 / −2.30% vs −1.86% semaglutide; 15 mg superior | PMID 34170647 |
| 5 / 10 / 15 mg | SC weekly (72 wk) | Human (SURMOUNT-1, obesity, no diabetes, n=2,539) | Mean weight −15.0 / −19.5 / −20.9% vs −3.1% placebo | PMID 35658024 |
| 10 or 15 mg | SC weekly (52 wk) | Human (SURMOUNT-OSA, obesity + sleep apnea) | Apnea-hypopnea index −25.3 (no PAP) / −29.3 (on PAP) events/hr vs placebo | PMID 38912654 |
Quick answers
Frequently asked
What is tirzepatide?
It is an FDA-approved dual agonist — a single peptide that activates both the GIP and the GLP-1 receptors. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea, given as a once-weekly injection under the skin.
How is tirzepatide different from semaglutide?
Semaglutide activates one receptor (GLP-1); tirzepatide activates two (GIP and GLP-1). In the SURPASS-2 head-to-head trial, tirzepatide produced larger blood-sugar and weight reductions than semaglutide. The superiority is demonstrated, but exactly how much the GIP arm adds is inferred, not measured separately in people.
How much weight does tirzepatide cause in trials?
In SURMOUNT-1, the 15 mg weekly dose produced about 20.9% mean body-weight loss over 72 weeks, versus about 3.1% on placebo — the largest of any approved weight-loss drug with published trial data. That is a supervised trial result with diet and lifestyle measures, not a guarantee.
Why does the dose start so low?
The gastrointestinal side effects — nausea, diarrhea, vomiting — are dose-related. Starting at 2.5 mg and stepping up by 2.5 mg every few weeks (a titration ladder) gives the gut time to adjust. The 2.5 mg starter dose is for tolerability and is not a maintenance dose.
Is tirzepatide banned in sport?
No. As of the 2026 WADA list, tirzepatide is on the WADA Monitoring Program — tracked but NOT prohibited. Some vendor sources incorrectly claim a full ban; per WADA's own 2026 documents it is monitored, not banned.
Does it affect birth control?
It can. By slowing gastric emptying it may make oral hormonal contraceptives less reliable, so the FDA label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
Primary sources
References
- PubChem CID 156588324PubChem CID 156588324 (Tirzepatide, free peptide)
- DailyMed (Mounjaro)DailyMed — Mounjaro (tirzepatide) label
- PMID 34170647Frías et al., NEJM 2021 (SURPASS-2, vs semaglutide)
- PMID 35658024Jastreboff et al., NEJM 2022 (SURMOUNT-1, obesity)
- PMID 38912654Malhotra et al., NEJM 2024 (SURMOUNT-OSA, sleep apnea)
- WADA 2026WADA 2026 Monitoring Program (GIP/GLP-1 agonists monitored, not prohibited)
Research use only · Not medical advice · Updated 2026-06-01